Fennec Pharmaceuticals Inc Financials
This page shows Fennec Pharmaceuticals Inc (FENC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Fennec Pharmaceuticals Inc has an operating margin of -14.1%, meaning the company retains $-14 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from 5.4% the prior year.
Fennec Pharmaceuticals Inc's revenue declined 6.1% year-over-year, from $47.5M to $44.6M. This contraction results in a growth score of 23/100.
Fennec Pharmaceuticals Inc carries a low D/E ratio of 0.99, meaning only $0.99 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 82/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 6.37, Fennec Pharmaceuticals Inc holds $6.37 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Fennec Pharmaceuticals Inc generates a -27.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.
Fennec Pharmaceuticals Inc passes 1 of 9 financial strength tests. No profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Fennec Pharmaceuticals Inc generates $1.28 in operating cash flow (-$12.5M OCF vs -$9.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Fennec Pharmaceuticals Inc earns $-3.0 in operating income for every $1 of interest expense (-$6.3M vs $2.1M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Fennec Pharmaceuticals Inc generated $44.6M in revenue in fiscal year 2025. This represents a decrease of 6.1% from the prior year.
Fennec Pharmaceuticals Inc reported -$9.7M in net income in fiscal year 2025. This represents a decrease of 2134.2% from the prior year.
Fennec Pharmaceuticals Inc earned $-0.34 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 1600.0% from the prior year.
Cash & Balance Sheet
Fennec Pharmaceuticals Inc held $36.8M in cash against $0 in long-term debt as of fiscal year 2025.
Fennec Pharmaceuticals Inc had 34M shares outstanding in fiscal year 2025. This represents an increase of 25.2% from the prior year.
Margins & Returns
Fennec Pharmaceuticals Inc's operating margin was -14.1% in fiscal year 2025, reflecting core business profitability. This is down 19.5 percentage points from the prior year.
Fennec Pharmaceuticals Inc's net profit margin was -21.8% in fiscal year 2025, showing the share of revenue converted to profit. This is down 20.9 percentage points from the prior year.
Fennec Pharmaceuticals Inc's ROE was -27.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Capital Allocation
Fennec Pharmaceuticals Inc invested $250K in research and development in fiscal year 2025. This represents a decrease of 18.6% from the prior year.
FENC Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.5M+29.1% | $9.7M+10.3% | $8.8M+10.4% | $7.9M+13.6% | $7.0M-4.0% | $7.3M-71.4% | $25.4M+160.7% | $9.7M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $685K |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $9.1M |
| R&D Expenses | $29K-72.9% | $107K+13.8% | $94K+88.0% | $50K-48.5% | $97K-38.2% | $157K+5133.3% | $3K-90.6% | $32K |
| SG&A Expenses | $6.8M-2.9% | $7.0M+13.2% | $6.1M+46.4% | $4.2M-31.4% | $6.1M-10.8% | $6.9M+16.9% | $5.9M-15.7% | $7.0M |
| Operating Income | -$189K+93.1% | -$2.7M-238.1% | -$808K+13.5% | -$934K+82.0% | -$5.2M-3.2% | -$5.0M-136.7% | $13.7M+855.9% | -$1.8M |
| Interest Expense | $586K-1.3% | $594K+0.3% | $592K-38.7% | $966K-5.8% | $1.0M-1.8% | $1.0M+1.0% | $1.0M-55.3% | $2.3M |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$638K+79.8% | -$3.2M-170.6% | -$1.2M+41.3% | -$2.0M+65.4% | -$5.7M-3.3% | -$5.6M-143.3% | $12.8M+578.6% | -$2.7M |
| EPS (Diluted) | $-0.02+81.8% | $-0.11-175.0% | $-0.04 | N/A | $-0.21-5.0% | $-0.20-148.8% | $0.41 | N/A |
FENC Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $49.3M+9.8% | $44.9M-3.3% | $46.4M+3.2% | $44.9M-23.7% | $58.9M-6.7% | $63.2M-8.7% | $69.2M+157.6% | $26.9M |
| Current Assets | $46.1M+12.9% | $40.8M-5.1% | $43.0M-2.6% | $44.1M-23.9% | $58.0M-6.8% | $62.2M-8.8% | $68.2M+153.8% | $26.9M |
| Cash & Equivalents | $21.9M+17.3% | $18.7M-17.5% | $22.7M-14.9% | $26.6M-33.9% | $40.3M-6.4% | $43.1M-15.9% | $51.2M+285.7% | $13.3M |
| Inventory | $2.5M+12.5% | $2.2M+56.8% | $1.4M+32.5% | $1.1M-5.8% | $1.1M-47.5% | $2.1M+3.9% | $2.1M-4.3% | $2.2M |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $53.8M+2.7% | $52.3M+0.1% | $52.3M+2.9% | $50.8M-20.7% | $64.1M-0.7% | $64.5M-2.5% | $66.2M+72.0% | $38.5M |
| Current Liabilities | $9.8M+16.7% | $8.4M+0.5% | $8.4M+21.0% | $6.9M-6.9% | $7.4M-4.1% | $7.7M-21.2% | $9.8M+30.2% | $7.6M |
| Long-Term Debt | $19.4M+0.1% | $19.4M+0.1% | $19.4M+0.1% | $19.3M-39.7% | $32.1M+1.0% | $31.8M+1.4% | $31.3M+1.4% | $30.9M |
| Total Equity | -$4.5M+39.8% | -$7.5M-26.9% | -$5.9M-0.1% | -$5.9M-13.6% | -$5.2M-281.1% | -$1.4M-145.0% | $3.0M+125.9% | -$11.6M |
| Retained Earnings | -$224.6M-0.3% | -$224.0M-1.4% | -$220.8M-0.5% | -$219.7M-0.9% | -$217.7M-2.7% | -$212.0M-2.7% | -$206.4M+5.9% | -$219.2M |
FENC Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.5M+140.5% | -$3.7M+14.6% | -$4.3M-192.9% | -$1.5M+33.2% | -$2.2M+73.7% | -$8.4M-121.5% | $39.0M+903.4% | -$4.9M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $1.7M+715.8% | -$284K-179.1% | $359K+102.9% | -$12.2M-2212.9% | -$528K-305.4% | $257K+122.7% | -$1.1M-119.8% | $5.7M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
FENC Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 93.0% |
| Operating Margin | -1.5%+26.8pp | -28.3%-19.1pp | -9.2%+2.6pp | -11.8%+62.8pp | -74.6%-5.2pp | -69.4%-123.6pp | 54.2%+72.8pp | -18.7% |
| Net Margin | -5.1%+27.5pp | -32.7%-19.4pp | -13.3%+11.7pp | -25.1%+57.2pp | -82.2%-5.8pp | -76.5%-127.1pp | 50.6%+78.1pp | -27.6% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | 425.9% | N/A |
| Return on Assets | -1.3%+5.7pp | -7.0%-4.5pp | -2.5%+1.9pp | -4.4%+5.3pp | -9.7%-0.9pp | -8.8%-27.3pp | 18.6%+28.5pp | -10.0% |
| Current Ratio | 4.69-0.2 | 4.85-0.3 | 5.13-1.2 | 6.38-1.4 | 7.80-0.2 | 8.02+1.1 | 6.93+3.4 | 3.56 |
| Debt-to-Equity | -4.31-1.7 | -2.59+0.7 | -3.290.0 | -3.29+2.9 | -6.21+17.2 | -23.42-33.8 | 10.40+13.1 | -2.66 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Fennec Pharmaceuticals Inc's annual revenue?
Fennec Pharmaceuticals Inc (FENC) reported $44.6M in total revenue for fiscal year 2025. This represents a -6.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Fennec Pharmaceuticals Inc's revenue growing?
Fennec Pharmaceuticals Inc (FENC) revenue declined by 6.1% year-over-year, from $47.5M to $44.6M in fiscal year 2025.
Is Fennec Pharmaceuticals Inc profitable?
No, Fennec Pharmaceuticals Inc (FENC) reported a net income of -$9.7M in fiscal year 2025, with a net profit margin of -21.8%.
What is Fennec Pharmaceuticals Inc's operating margin?
Fennec Pharmaceuticals Inc (FENC) had an operating margin of -14.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Fennec Pharmaceuticals Inc's net profit margin?
Fennec Pharmaceuticals Inc (FENC) had a net profit margin of -21.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Fennec Pharmaceuticals Inc's return on equity (ROE)?
Fennec Pharmaceuticals Inc (FENC) has a return on equity of -27.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Fennec Pharmaceuticals Inc's operating cash flow?
Fennec Pharmaceuticals Inc (FENC) generated -$12.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Fennec Pharmaceuticals Inc's total assets?
Fennec Pharmaceuticals Inc (FENC) had $70.6M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Fennec Pharmaceuticals Inc spend on research and development?
Fennec Pharmaceuticals Inc (FENC) invested $250K in research and development during fiscal year 2025.
What is Fennec Pharmaceuticals Inc's current ratio?
Fennec Pharmaceuticals Inc (FENC) had a current ratio of 6.37 as of fiscal year 2025, which is generally considered healthy.
What is Fennec Pharmaceuticals Inc's debt-to-equity ratio?
Fennec Pharmaceuticals Inc (FENC) had a debt-to-equity ratio of 0.99 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Fennec Pharmaceuticals Inc's return on assets (ROA)?
Fennec Pharmaceuticals Inc (FENC) had a return on assets of -13.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Fennec Pharmaceuticals Inc's cash runway?
Based on fiscal year 2025 data, Fennec Pharmaceuticals Inc (FENC) had $36.8M in cash against an annual operating cash burn of $12.5M. This gives an estimated cash runway of approximately 35 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Fennec Pharmaceuticals Inc's Piotroski F-Score?
Fennec Pharmaceuticals Inc (FENC) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Fennec Pharmaceuticals Inc's earnings high quality?
Fennec Pharmaceuticals Inc (FENC) has an earnings quality ratio of 1.28x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Fennec Pharmaceuticals Inc cover its interest payments?
Fennec Pharmaceuticals Inc (FENC) has an interest coverage ratio of -3.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Fennec Pharmaceuticals Inc?
Fennec Pharmaceuticals Inc (FENC) scores 41 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.